SurgoCap Partners LP
$3.1B in tracked AUM across 13 positions as of Q2 2026.
SurgoCap Partners LP is a $2.99B hedge fund with a 79-whaleScore that runs a deliberately concentrated active book — no core passive anchor, no market-making veneer. Top positions include quality-sovereign names like Johnson & Johnson, Microsoft, and Eli Lilly alongside more opportunistic picks in cyclical and small-cap territory. The portfolio shrank from $3.61B to $2.99B quarter-over-quarter, a 17% reduction that reflects net selling rather than market depreciation alone. The most interesting structural observation is the absence of a stabilizing large-position: no single holding exceeds 8% of the portfolio, which for a $3B active manager implies either a deliberately diversified conviction model or a book that is still in the process of concentrating. SurgoCap's whaleScore suggests the former — a manager who earns alpha from sector and security selection across a 60-name book rather than from a handful of high-conviction wagers.
Quarter at a glance — Q2 2026
Position-change comparison pending.
Top 10 holdings
By portfolio weight as of Q2 2026.